<rdf:RDF
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:j.0="http://www.ddmore.org/ontologies/webannotationtool#"
    xmlns:j.1="http://www.pharmml.org/ontology/"
    xmlns:j.2="http://www.pharmml.org/2013/10/PharmMLMetadata#" > 
  <rdf:Description rdf:about="http://repository.ddmore.eu/model/DDMODEL00000192">
    <rdf:type rdf:resource="http://www.pharmml.org/ontology/PHARMMLO_0000001"/>
    <j.2:model-has-description-long rdf:datatype="http://www.w3.org/2001/XMLSchema#string">The PK is modelled by a one compartment first order absorption model. The inhibition of TGFbeta signalling by the treatment is represented by a turnover model, that is a simplification of the semi-mechanistic model developed by Bueno et al.</j.2:model-has-description-long>
    <j.0:model-implementation-conforms-to-literature-controlled rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Yes</j.0:model-implementation-conforms-to-literature-controlled>
    <j.2:model-modelling-question rdf:resource="http://www.ddmore.org/ontologies/ontology/pkpd-ontology#pkpd_0006028"/>
    <j.0:model-origin-of-code-in-literature-controlled rdf:datatype="http://www.w3.org/2001/XMLSchema#string">No</j.0:model-origin-of-code-in-literature-controlled>
    <j.2:model-tasks-in-scope rdf:resource="http://www.ddmore.org/ontologies/ontology/pkpd-ontology#pkpd_0006002"/>
    <j.2:model-field-purpose rdf:resource="http://www.ddmore.org/ontologies/ontology/pkpd-ontology#pkpd_0000036"/>
    <j.2:model-research-stage rdf:resource="http://www.ddmore.org/ontologies/ontology/pkpd-ontology#pkpd_0006009"/>
    <j.2:model-has-description rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PKPD model developed for a small molecule TGFbeta inhibitor.</j.2:model-has-description>
    <j.0:model-implementation-source-discrepancies-freetext rdf:datatype="http://www.w3.org/2001/XMLSchema#string">No discrepancy</j.0:model-implementation-source-discrepancies-freetext>
  </rdf:Description>
</rdf:RDF>
